ClotCare: Blood Clots, Stroke, Heart Attack
Monday, October 23, 2017
Home   |   DVT/PE   |   Blood Clots   |   Coumadin/Warfarin   |   New Patients   |   Self Testing   |   Email List   |   Donate

Pick a Topic:

Find info on a:

We subscribe to the HONcode principles of the HON Foundation. Click to verify.
ClotCare complies with the HONcode standard for trustworthy health
information:
verify here.

ClotCare is a member of the Coalition to Prevent Deep Vein Thrombosis (DVT Coalition)  ClotCare is a member organization of the Coalition to Prevent Deep Vein Thrombosis. Click here to learn more about the Coalition to Prevent Deep Vein Thrombosis and DVT Awareness Month, which is held each March.

FDA Rejects Ximelagatran (brand name Exanta)

Henry I. Bussey, Pharm.D.
October 2004

As previously reported on ClotCare, the FDA Cardiovascular and Renal Drugs Advisory Committee recently voted against recommending approval for ximelagatran based on concerns about liver toxicity, the company's proposed system for monitoring liver function tests in patients taking the drug, and the surprise finding of a possible increase in heart attacks with the drug. While the FDA usually follows the recommendation of its advisory panel, many believed that the final decision would not be forthcoming until late in October, 2005. In a press release dated October 11, 2004, however, AstraZeneca has announced that the FDA has decided not to grant approval for the drug. This decision also is being reported on Heartwire, and interestingly, the Heartwire report indicates that the FDA decision was based in part on what may have been three fatalities related to hepatoxicity of the drug. Most earlier information had suggested that the reported increase in liver enzymes were asymptomatic and transient with reversal to normal values occurring even with continuation of the drug.

Links to References & News Coverage

AstraZeneca Press Release

HeartWire

Reuters

Ask a question about blood clots or anticoagulant medications Have questions? Ask ClotCare. Send questions by email to webmaster@clotcare.org.

ClotCare is a 501(c)(3) non-profit organization generously supported by your tax-deductible donations and grants from our industry supporters.

Blood Clot Activities Calendar

New Postings:

World Thrombosis Day - Oct. 13, 2017

Rivaroxaban or Warfarin in Stable Coronary Artery Disease – Should the COMPASS Study Lead Us Back to the Future?

Click here to view full list of new postings
ClotCare Home | New Postings | Patient Postings | Clinician Postings | Join Our Email List | Useful Web Links
CE Opportunities | Training Programs | DVT & PE Stories | Editorial Board | Financial Support
About ClotCare | DVT Coalition | Donate to ClotCare | Contact Us
Key topics discussed on ClotCare include: Blood Clots | Deep Vein Thrombosis (DVT) | Pulmonary Embolism (PE) | Atrial Fibrillation (A. Fib or AF) | Heart Attack | Stroke | Transient Ischemic Attack (TIA) | Mini Stroke | Bleeding Complications | Vascular Surgery | Surgical Blood Clot Removal | Warfarin | Coumadin | Lovenox | Low Molecular Weight Heparin (LMWH) | Heparin | Anticoagulants | Plavix | Aspirin | Antiplatelets | Blood Thinners
Copyright 2000-2014 by ClotCare. All rights reserved.
Terms, Conditions, & Privacy | Image Copyright Information
19260 Stone Oak Parkway, Suite 101 | San Antonio, TX 78258 | 210-495-4335
Send comments to webmaster@clotcare.org.
Monday, October 23, 2017